FogPharma was born from the scientific and entrepreneurial vision of founder Dr. Gregory Verdine, a pioneer in the discovery and development of new drug classes that 'drug the undruggable.' FogPharma's cell-penetrating miniproteins are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together with world-leading experts and collaborators in translational medicine, the FogPharma team is building a drug discovery platform to develop fundamentally new treatments for cancer and other life-threatening diseases. Co-founded in 2015 by academic scientist, biotech entrepreneur, investor, and chief executive Dr. Verdine, FogPharma is headquartered in Cambridge, Mass. and has raised $77 million in funding as of May 2018.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/21/18 | $66,000,000 | Series B |
6 Dimensions Capital Blue Pool Capital Boyu Capital Deerfield Management Company, L.P. Horizons Ventures Nan Fung WuXi AppTec | undisclosed |
| 03/02/21 | $107,000,000 | Series C |
6 Dimensions Capital Blue Pool Capital Casdin Capital Cormorant Asset Management Deerfield Management Company, L.P. Farallon Capital Management GV HBM Healthcare Investments Invus PAGS Group T. Rowe Price Associates VenBio | undisclosed |
| 11/21/22 | $178,000,000 | Series D |
ARCH Venture Partners Casdin Capital Cormorant Asset Management Deerfield Management Company, L.P. Farallon Capital Management Fidelity Management & Research Company GV HBM Healthcare Investments Invus Milky Way Ventures PagsGroup T. Rowe Price Associates VenBio | undisclosed |
